Get the Stockscreener App
9.67
8.53%
0.76
After Hours:
9.67
Tango Therapeutics Inc stock is traded at $9.67, with a volume of 1.75M.
It is up +8.53% in the last 24 hours and up +0.42% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$8.91
Open:
$8.89
24h Volume:
1.75M
Relative Volume:
0.56
Market Cap:
$1.30B
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-7.2707
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
+12.05%
1M Performance:
+0.42%
6M Performance:
+69.65%
1Y Performance:
+217.05%
1-Day Range:
$8.89
$9.69
1-Week Range:
$8.55
$9.69
52-Week Range:
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
9.67 | 1.20B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics Adds Independent Director to Strengthen Governance - TipRanks
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com India
Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire
What analysts say about Tango Therapeutics Inc stockGap Fill Strategies & Superior Wealth Building - earlytimes.in
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq index Notes Liquidity Move - Kalkine Media
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - WV News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tango Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Sentiment & Fast Entry High Yield Tips - Улправда
Will Tango Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Trends & AI Driven Stock Reports - Улправда
Why Tango Therapeutics Inc. stock remains a top recommendationMarket Trend Report & Technical Pattern Based Signals - DonanımHaber
Will Tango Therapeutics Inc. stock deliver strong dividend growthProduct Launch & Real-Time Volume Analysis - DonanımHaber
Can Tango Therapeutics Inc. stock sustain market leadershipDay Trade & Verified Swing Trading Watchlist - DonanımHaber
Can Tango Therapeutics Inc. stock reach $100 price target2025 Sector Review & High Accuracy Swing Entry Alerts - Улправда
5 Biotech Stocks to Watch for Potential Upside - The Globe and Mail
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 7.6%Here's What Happened - MarketBeat
Is Tango Therapeutics (TNGX) Overvalued After a 200% One-Year Surge? A Fresh Look at Its Pricing - Yahoo Finance
Highs Report: Is Tango Therapeutics Inc stock a defensive play in 2025Portfolio Performance Report & Risk Managed Investment Signals - moha.gov.vn
Tango Therapeutics (NASDAQ:TNGX) Raised to Buy at Wall Street Zen - MarketBeat
Stempoint Capital LP Acquires Shares of 208,800 Tango Therapeutics, Inc. $TNGX - MarketBeat
Can Tango Therapeutics (TNGX) climb 37.28% to reach the level Wall Street analysts expect? - MSN
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 4.6%Should You Sell? - MarketBeat
Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd - MarketBeat
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? - Finviz
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32% - simplywall.st
Geode Capital Management LLC Grows Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
How interest rate cuts could boost Tango Therapeutics Inc. stockMarket Risk Analysis & Daily Profit Focused Screening - Newser
Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation - Nasdaq
Is Tango Therapeutics Inc. stock near bottom after declineJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com Nigeria
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target By Investing.com - Investing.com South Africa
Piper Sandler Healthcare Conference - marketscreener.com
Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Tango Therapeutics Stock Hold Up When Markets Turn? - Trefis
Retail Trends: How interest rate cuts could boost Tango Therapeutics Inc stockRecession Risk & Fast Exit Strategy with Risk Control - moha.gov.vn
Tango Therapeutics Inc trading resumes - MSN
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):